Advanced search

Project: An mRNA replicon based immunotherapeutic combinational treatment for triple negative breast cancer

01/01/16 – 31/12/19

Our recently developed mRNA replicon platform will be used to develop a novel immunotherapeutic combinatorial treatment for triple-negative breast cancer. The treatment consists of three parts: (1) an mRNA replicon based therapeutic cancer vaccine coding for the universal tumor-associated antigen p62, (2) an mRNA replicon that produces IL-12 under the control of a registered drug, and (3) an anti-PD-L1 immune checkpoint inhibitor